2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Xembify: new trials by email Literature Review of Xembify trials Research Report on Xembify
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-04-02 | 2026-10-09 |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | Grifols Therapeutics LLC | 386 | 2022-12-26 | 2026-09-30 |
Agammaglobulinemia (1) · Bacterial Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)
Poland (2) · Romania (2) · United States (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Hungary (1) · Serbia (1)